1e
19
1
49
2
2
18
1b
1d
18
2f
8c
1d
2 29
1d
25
Elise A Chong, MD
88
8c
Assistant Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
7
5f
Department: Medicine
4
1
b
1d
46
Contact information
54
4
3
3
3
2
4
b
1f
54
Perelman Center for Advanced Medicine
1f 3400 Civic Center Blvd
3d 12th Floor, South Pavilion
Philadelphia, PA 19104
26
1f 3400 Civic Center Blvd
3d 12th Floor, South Pavilion
Philadelphia, PA 19104
35
f
13
Education:
21 7 AB 2e (Ecology and Evolutionary Biology ) c
2d Princeton University, 2007.
21 f Non-degree 23 (Graduate courses ) c
33 University of Pennsylvania, 2009.
21 7 MD 1b (Medical Degree) c
51 Perelman School of Medicine, University of Pennsylvania , 2013.
c
3
3
3
3
8d
Permanent link21 7 AB 2e (Ecology and Evolutionary Biology ) c
2d Princeton University, 2007.
21 f Non-degree 23 (Graduate courses ) c
33 University of Pennsylvania, 2009.
21 7 MD 1b (Medical Degree) c
51 Perelman School of Medicine, University of Pennsylvania , 2013.
c
2 29
21
1e
1d
24
2b
29
27
23
224 Svoboda J, Landsburg DJ, Gerson J, Nasta SD, Barta SK, Chong EA, Cook M, Frey NV, Shea J, Cervini A, Marshall A, Four M, Davis MM, Jadlowsky JK, Chew A, Pequignot E, Gonzalez V, Noll JH, Paruzzo L, Rojas-Levine J, Plesa G, Scholler J, Siegel DL, Levine BL, Porter DL, Ghassemi S, Ruella M, Rech A, Leskowitz RM, Fraietta JA, Hwang WT, Hexner E, Schuster SJ, June CH.: Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure. N Engl J Med 392(18): 1824-1835, May 2025.
16a Ni V, Nasta SD, Barta SK, Schuster SJ, Chong EA, Svoboda J, Morrissette JJD, Barlev A, Bagg A, Priore SF, Landsburg DJ: Identification of a clinicopathologic prognostic index for newly diagnosed large B-cell lymphoma patients treated with R-CHOP. Haematologica 110(4): 1023-1027, Apr 2025.
180 Dave NK, Carvajal V, Watts AC, Carter JS, Cook M, Thomas C, Tsai DE, Schuster SJ, Gerson JN, Barta SK, Svoboda J, Chong EA, Hwang WT, Landsburg DJ, Nasta SD.: Outcomes at a single institution with MTR induction and consolidation in the management of primary CNS lymphoma Blood Neoplasia 2(3): 100102, Apr 2025.
190 Elghawy O, Sussman JH, Yang AG, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK: Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome. JAMA Dermatol Apr 2025 Notes: Epub ahead of print.
1d0 Maillie L, Nasta SD, Svoboda J, Barta SK, Chong EA, Garfall AL, Gill SI, Porter DL, Schuster SJ, Catania C, Frey NV, Landsburg DJ: Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B-cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell Therapy. Transplantation and Cellular Therapy 31(4): 228-235, Apr 2025.
1dc Elghawy O, Yang AG, Sussman JH, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Villasenor-Park J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK: Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome. J Am Acad Dermatol 92(3): 634-636, Mar 2025.
188 Elghawy O, Wang J, Leung OJ, Swami N, Carvajal V, Yang G, Landsburg DJ, Svoboda J, Nasta SD, Chong EA, Schuster SJ, Thomas CJ, Carter JS, Bagg A, Barta SK: Clinical Impact of Next-Generation Sequencing of T-Cell Lymphomas: A Single Institution Experience. Clin Lymphoma Myeloma Leuk Feb 2025 Notes: Epub ahead of print.
2c 298 Adam S Kittai AS, Ying Huang Y 2 , Sarah Miller S, John N Allan JN, Bhat SA, Bond DA, Brander DM, Byrd JC, Chavez JC, Chong E, Davids MS, Danilov AV, Ding W, Dowling MR, Dvorak-Kornaus K, Freedman H, Hampel PJ, Ho C, Hwang SR, Islam P, Malakhov N, Matasar M, Miller C, Omer Z, Parikh SA, Parry E, Rabe KG, Raess PW, Rai M, Roeker L, Rhodes J, Rogers KA, Saha A, Schade J, Scott HW, Shadman M, Shouse G, Skarbnik A, Spurgeon S, Stephens DM, Thompson MC, Thompson PA, Wang Y, Yano M, Woyach JA: Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL. Blood Cancer J 15(1): 23, Feb 2025.
1b2 Chong EA, Penuel E, Napier EB, Lundberg RK, Budde LE, Shadman M, Matasar MJ, Bartlett NL, Flinn IW, Bosch F, Fay K, Goy A, Kumar A, Nastoupil LJ, Wei MC, Wu M, Yin S, Fraietta JA, Chong ER, Schuster SJ: Impact of prior CAR-T cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas. Blood Advances 9(4): 696-703, Feb 2025.
2c
7
1d
1f
Selected Publications
196 Yegya-Raman N, Plastaras JP, Wright CM, Chelius M, Zhang S, Baron JA, Hubbeling H, Sim AJ, Robinson TJ, Jain MD, Imber B, Fregonese B, Yahalom J, Ladbury C, Dandapani S, Pinnix CC, Gunther JR, Fang PQ, Wu SY, Dabaja BS, Yang JC, Chew J, Braunstein S, Sinha S, Delinger NM, Sun S, Terezakis SA, Sakthivel G, Constine LS, Chowdhry AK, Reagan PM, Burke S, Tseng YD, 11a LaRiviere MJ, Maity A, Schuster SJ, Chong EA,** Figura NB**: Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cells for B-Cell Lymphomas: An ILROG Multicenter Study. Blood Advances 9(13): 3293-3303, Jul 2025 Notes: **co-corresponding author.224 Svoboda J, Landsburg DJ, Gerson J, Nasta SD, Barta SK, Chong EA, Cook M, Frey NV, Shea J, Cervini A, Marshall A, Four M, Davis MM, Jadlowsky JK, Chew A, Pequignot E, Gonzalez V, Noll JH, Paruzzo L, Rojas-Levine J, Plesa G, Scholler J, Siegel DL, Levine BL, Porter DL, Ghassemi S, Ruella M, Rech A, Leskowitz RM, Fraietta JA, Hwang WT, Hexner E, Schuster SJ, June CH.: Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure. N Engl J Med 392(18): 1824-1835, May 2025.
16a Ni V, Nasta SD, Barta SK, Schuster SJ, Chong EA, Svoboda J, Morrissette JJD, Barlev A, Bagg A, Priore SF, Landsburg DJ: Identification of a clinicopathologic prognostic index for newly diagnosed large B-cell lymphoma patients treated with R-CHOP. Haematologica 110(4): 1023-1027, Apr 2025.
180 Dave NK, Carvajal V, Watts AC, Carter JS, Cook M, Thomas C, Tsai DE, Schuster SJ, Gerson JN, Barta SK, Svoboda J, Chong EA, Hwang WT, Landsburg DJ, Nasta SD.: Outcomes at a single institution with MTR induction and consolidation in the management of primary CNS lymphoma Blood Neoplasia 2(3): 100102, Apr 2025.
190 Elghawy O, Sussman JH, Yang AG, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK: Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome. JAMA Dermatol Apr 2025 Notes: Epub ahead of print.
1d0 Maillie L, Nasta SD, Svoboda J, Barta SK, Chong EA, Garfall AL, Gill SI, Porter DL, Schuster SJ, Catania C, Frey NV, Landsburg DJ: Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B-cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell Therapy. Transplantation and Cellular Therapy 31(4): 228-235, Apr 2025.
1dc Elghawy O, Yang AG, Sussman JH, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Villasenor-Park J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK: Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome. J Am Acad Dermatol 92(3): 634-636, Mar 2025.
188 Elghawy O, Wang J, Leung OJ, Swami N, Carvajal V, Yang G, Landsburg DJ, Svoboda J, Nasta SD, Chong EA, Schuster SJ, Thomas CJ, Carter JS, Bagg A, Barta SK: Clinical Impact of Next-Generation Sequencing of T-Cell Lymphomas: A Single Institution Experience. Clin Lymphoma Myeloma Leuk Feb 2025 Notes: Epub ahead of print.
2c 298 Adam S Kittai AS, Ying Huang Y 2 , Sarah Miller S, John N Allan JN, Bhat SA, Bond DA, Brander DM, Byrd JC, Chavez JC, Chong E, Davids MS, Danilov AV, Ding W, Dowling MR, Dvorak-Kornaus K, Freedman H, Hampel PJ, Ho C, Hwang SR, Islam P, Malakhov N, Matasar M, Miller C, Omer Z, Parikh SA, Parry E, Rabe KG, Raess PW, Rai M, Roeker L, Rhodes J, Rogers KA, Saha A, Schade J, Scott HW, Shadman M, Shouse G, Skarbnik A, Spurgeon S, Stephens DM, Thompson MC, Thompson PA, Wang Y, Yano M, Woyach JA: Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL. Blood Cancer J 15(1): 23, Feb 2025.
1b2 Chong EA, Penuel E, Napier EB, Lundberg RK, Budde LE, Shadman M, Matasar MJ, Bartlett NL, Flinn IW, Bosch F, Fay K, Goy A, Kumar A, Nastoupil LJ, Wei MC, Wu M, Yin S, Fraietta JA, Chong ER, Schuster SJ: Impact of prior CAR-T cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas. Blood Advances 9(4): 696-703, Feb 2025.
2c